| Novel Agents in the Treatment of Chronic Lymphocytic Leukemia |
|
Chul Won Choi |
|
Division of Oncology and Hematology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea |
| 만성 림프구 백혈병의 새로운 치료 |
|
최철원 |
|
고려대학교 의과대학 구로병원 종양혈액내과 |
Correspondence:
Chul Won Choi, Tel: +82-2-2626-3058, Fax: +82-2-862-6453, Email: bonnie@korea.ac.kr
|
|
|
|
|
| This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Abstract |
|
Chronic lymphocytic leukemia (CLL) is an indolent B-cell leukemia, and the most common leukemia in the Western world. While CLL is currently a rare leukemia type in Korea, the prevalence of CLL is expected to rise in the future. The clinical course is extremely heterogeneous and can range from asymptomatic to rapidly progressive disease. Chemoimmunotherapy (rituximab + fludarabine + cyclophosphamide) has become the standard front-line therapy in young fit patients with normal renal function. Despite the development of more intensive new treatments, these new therapies are not suitable for all patients with CLL. Novel targeted therapies, such as small molecules that disrupt the B-cell receptor pathway or new monoclonal antibodies, have emerged as promising therapeutic options. Prospective clinical trials exploring the efficacy and toxicity profiles of new agents, alone or in combination with other treatments, will reveal whether these novel agents could replace the current standard regimens. |
| Key Words:
Chronic lymphocytic leukemia (CLL); Prospective studies; Treatment |
| 주제어:
만성 림프구 백혈병; 전향적 연구; 치료 |
|
PDF Links
Full text via DOI
Download Citation
